To identify potential therapeutics that could increase PKD1 expression in individuals with ADPKD, we conducted an in silico perturbation experiment using an LPM trained on pooled LINCS compound and genetic perturbation data to predict which clinical-stage drugs may lead to upregulation in PKD1 levels in HA1E embryonic kidney cells cultured under the LINCS L1000 protocol54. The gene discussed is PKD1; the disease is autosomal dominant polycystic kidney disease.